EGFR and non-small cell lung carcinoma: Additionally, due to its significant clinical benefits in uncommon EGFR mutations such as G719X, S768I, L861Q, and some compound mutations (defined as ≥2 EGFR mutations and at least one uncommon EGFR mutation), afatinib is currently the only EGFR TKI approved for advanced NSCLC patients with G719X/L861Q/S768I (30).